Leerink Partnrs Has Bearish Estimate for ELEV Q2 Earnings
Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) – Analysts at Leerink Partnrs cut their Q2 2025 EPS estimates for Elevation Oncology in a note issued to investors on Monday, June 9th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($0.36) for the quarter, down from their previous […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) – Analysts at Leerink Partnrs cut their Q2 2025 EPS estimates for Elevation Oncology in a note issued to investors on Monday, June 9th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($0.36) for the quarter, down from their previous […]
